Medtronic Evaluates Insertable Cardiac Monitor to Identify Patients at High Risk of Worsening Heart Failure
- Medtronic enrolls the first patient in the ALLEVIATE-HF clinical trial assessing the ability of its Reveal LINQ ICM in identifying patients at high risk of worsening HF. The study will enroll ~300 patients at up to 30 sites across the US for a minimum of 7mos.and up to 3yrs.
- The focus of the study is to determine if early information provided by the LINQ devices enables clinicians to act before patients' conditions worsen. The ICM allows physicians to monitor a patient’s heart continuously and wirelessly for arrhythmia disorder
- The Reveal LINQ ICM is ~ one-third the size of a AAA battery (~1 cc) and is placed just beneath the skin through a small incision of less than 1 cm in the upper left side of the chest- using a minimally invasive procedure. ALLEVIATE-HF trial is the first to study the use of an ICM to manage heart failure in a remote setting
Ref: Medtronic | Image: WebMD
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at firstname.lastname@example.org